bortezomib [clinicaltrials_resource:04e70d03e6b1bce5d42e472049a3c752]
intervention [clinicaltrials_vocabulary:intervention]
bortezomib [clinicaltrials_resource:04e70d03e6b1bce5d42e472049a3c752]
Bio2RDF identifier
04e70d03e6b1bce5d42e472049a3c752
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:04e70d03e6b1bce5d42e472049a3c752
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
intervention name [clinicaltrials_vocabulary:intervention-name]
bortezomib
other name [clinicaltrials_vocabulary:other-name]
identifier
clinicaltrials_resource:04e70d03e6b1bce5d42e472049a3c752
title
bortezomib
@en
type
label
bortezomib [clinicaltrials_resource:04e70d03e6b1bce5d42e472049a3c752]
@en